Comparative Pharmacology
Head-to-head clinical analysis: LERITINE versus MS CONTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LERITINE versus MS CONTIN.
LERITINE vs MS CONTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LERITINE (anileridine) is a synthetic opioid analgesic that acts as a mu-opioid receptor agonist, modulating pain perception and emotional response to pain.
Mu-opioid receptor agonist; binds to mu-opioid receptors in the CNS, modulating pain perception and emotional response to pain.
Adults: 25-50 mg orally every 6 hours as needed for pain; not to exceed 200 mg/day.
Oral: 15-30 mg every 8-12 hours; adjust based on pain severity and prior opioid use. Extended-release tablets must be swallowed whole; do not crush or chew. For opioid-naïve patients, start at 15 mg every 12 hours.
None Documented
None Documented
2-3 hours (terminal half-life in adults; may be prolonged in hepatic impairment or elderly, dosing adjustments recommended)
Terminal elimination half-life: 11-13 hours (range 8-24 hours). In elderly or hepatic impairment, half-life may be prolonged; acute dosing half-life ~2-4 hours.
Renal (70-90% as unchanged drug and metabolites); biliary/fecal (10-30%)
Renal: ~90% (mostly as morphine-3-glucuronide and morphine-6-glucuronide, with ~10% as unchanged morphine); Fecal: <10%
Category C
Category C
Opioid Analgesic
Opioid Analgesic